← FDA DRUG APPROVALS

FDA ANDA · ANDA218070

LIOTHYRONINE SODIUM

Sponsor: BIOCON PHARMA

APPLICATION
ANDA218070
TYPE
ANDA
ORIGINAL APPROVAL
2024-02-06
LATEST ACTION
2024-02-06
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LIOTHYRONINE SODIUMPrescription
LIOTHYRONINE SODIUM EQ 0.025MG BASE · TABLET · ORAL
LIOTHYRONINE SODIUMPrescription
LIOTHYRONINE SODIUM EQ 0.05MG BASE · TABLET · ORAL
LIOTHYRONINE SODIUMPrescription
LIOTHYRONINE SODIUM EQ 0.005MG BASE · TABLET · ORAL

Approval history

2024-02-06UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →